Bintai Kinden's Partner Signs Deal To Develop, Commercialise COVID-19 Vaccines

KUALA LUMPUR, Nov 5 (Bernama)-- Bintai Kinden Corporation Bhd’s partner, Generex Biotechnology Corporation, has signed a Framework Agreement for the development and commercialisation of the Ii-Key-SARS-CoV-2 coronavirus vaccine in China. The agreement was signed with the Chinese Center for Disease Control and Prevention (China CDC), Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co Ltd. In a statement today, Bintai Kinden said under the agreement, Generex would receive up-front development fees and back-end licensing payments. Meanwhile, the partners would undertake research and development, and pay 100 per cent of the funding required for the commercial approval of the Ii-Key-CoV-2 vaccine, including laboratory work, manufacturing, regulatory filings and the clinical development programme for regulatory approval of the vaccine in China. It said the Ii-Key-SARS-CoV-2 vaccine was designed as a “complete vaccine” that has the potential to induce the T-Cell and antibody immune responses in a highly specific manner that could provide protective immunity with long-lasting immunologic memory against SARS-CoV-2 and other pandemic threats like COVID-19 and swine flu. Managing director Ong Choon Lui said the partnership between Generex, China CDC, Beijing Guoxin Haixiang and Beijing Youfeng reaffirmed Ii-Key technology’s potential in developing safe and effective vaccines for infectious diseases and cancer. “The involvement of China’s state-owned fund and cooperation at the highest government level through the China CDC increases the likelihood of success of the vaccine commercialisation efforts,” he said. Bintai Kinden said its subsidiary, Bintai Healthcare Sdn Bhd, had signed an agreement with Generex and its subsidiary, NuGenerex Immuco-Oncology Inc in October for the distribution and licensing of their COVID-19 vaccine in Malaysia. It said the agreement granted Bintai Healthcare exclusive rights to distribute, sell and commercialise the COVID-19 vaccine in Malaysia, Brunei, Myanmar, Cambodia, Timor-Leste, Indonesia, Laos, the Philippines, Singapore, Thailand and Vietnam. “It will also have the right of first refusal to commercially exploit the vaccine within New Zealand, Australia and the global halal market,” it added. China CDC is a governmental and national-level technical organisation specialising in disease control and prevention and public health, and Beijing Guoxin Haixiang is a limited partnership established to fund the research and development efforts of the partnership. Meanwhile, Beijing Youfeng is the China High-Tech Industrialisation Research Society Public Health Working Committee which provides development strategy consulting and design, project implementation and management. --BERNAMA